Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…
iSpecimen Inc.
Next earnings ≈ Aug 17, 2026 · est. from filing cadence
Revenue fell -79.2% YoY.
Rules-based read computed from SEC figures — no Anthropic key set. Add ANTHROPIC_API_KEY to .env.local for a full Claude analysis.
iSpecimen Inc. shows $1.93M in FY2025 revenue (-79.2% YoY), a -543.7% net margin, and -339.6% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
Sources: SEC EDGAR (CIK 0001558569, latest 10-Q filed 2026-05-18) · EODHD · rules-based read · as of 6/18/2026, 1:07:17 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | $9.93M | $9.29M | $1.93M |
| Gross profit | — | — | — | — | — |
| Operating income | -$5.93M | -$10.2M | -$11.2M | -$12.7M | -$8.98M |
| Net income | -$8.96M | -$10.2M | -$11.1M | -$12.5M | -$10.5M |
| Diluted EPS | -$2.09 | -$1.16 | -$24.55 | -$17.58 | -$2.28 |
| Net margin | — | — | -111.8% | -134.5% | -543.7% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
501 tracked peers · median